Cetera Advisor Networks’s Acadia Pharmaceuticals ACAD Stock Holding History

Cetera Advisor Networks’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-715	Closed	-$35K	–	1245
2020 Q2	$35K	Buy	+715	New	+$34.3K	﹤0.01%	2097
2014 Q4	–	Sell	-9,755	Closed	-$239K	–	819
2014 Q3	$239K	Buy	+9,755	New	+$228K	0.02%	688
2013 Q4	–	Sell	-8,565	Closed	-$234K	–	762
2013 Q3	$234K	Buy	+8,565	New	+$179K	0.02%	566

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

PAMU

Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return

Cetera Advisor Networks's ACAD Position: Q3 2020 in Review

Cetera Advisor Networks sold out of Acadia Pharmaceuticals (ACAD) in Q3 2020, closing a stake of 715 shares — an estimated $35K sold.

Cetera Advisor Networks first reported a position in ACAD in Q3 2013 and held it in 3 quarters. The position peaked at $239K in Q3 2014. 267 funds tracked by Wall St. Rank hold ACAD as of Q3 2020.

Cetera Advisor Networks reported no remaining Acadia Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
Cetera Advisor Networks sold 715 Acadia Pharmaceuticals shares in Q3 2020, an estimated $35K.
Cetera Advisor Networks first reported a position in Acadia Pharmaceuticals in Q3 2013 and held it in 3 quarters.
Cetera Advisor Networks's Acadia Pharmaceuticals position peaked at $239K in Q3 2014.
267 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2020.

Based on Cetera Advisor Networks's 13F filing for Q3 2020, filed 13 Nov 2020.